Skip to content
HCC Buddy home

C84.7B ICD-10-CM Code: Anaplastic large cell lymphoma, ALK-negative, in remission

C84.7B maps to CMS-HCC V28 19. A source-labeled RAF reference is available. Confirm the documented diagnosis and applicable coding requirements. MEAT criteria · RAF Calculator · HCC Buddy coding tools

ICD-10-CM Code View

HCC Buddy Code Card

Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.

Code lookupC84.7B

FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)

C84.7B

Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidance

Anaplastic large cell lymphoma, ALK-negative, in remission

This is a type of aggressive blood cancer (lymphoma) that affects immune cells and does not have a specific genetic marker (ALK-negative), and the patient is currently in remission, meaning the cancer is not actively growing or detectable.

Buddy the Bee presenting code insight

Buddy Insight

Anaplastic large cell lymphoma, ALK-negative, in remission indicates the patient has achieved disease control from this aggressive lymphoma.

OverviewRisk ModelsCode BookDocumentationAuditNotesEdition comparison

CMS-HCC V28

HCC 19

Coefficient HCC 19: 1.798 (Community Non-Dual Aged (CNA))

CMS-HCC V24

Historical

Historical

Not used for CY2026 payment

ACA/HHS

HCC 010

Code-level coefficient reference

ESRD/PACE

HCC 10

Code-level coefficient reference

RXHCC

HCC 21

Code-level coefficient reference

Code Book Path

Official
C84Mature T/NK-cell lymphomasC84.7Anaplastic large cell lymphoma, ALK-negativeC84.7BAnaplastic large cell lymphoma, ALK-negative, in remission

Inclusion Terms

Official

No inclusion terms are included in this display for C84.7B. Check the code and parent instructions in the Code Book.

Excludes 2

Official
  • Kaposi's sarcoma of lymph nodes (C46.3)Inherited from C81-C96
  • secondary and unspecified neoplasm of lymph nodes (C77.-)Inherited from C81-C96
  • secondary neoplasm of bone marrow (C79.52)Inherited from C81-C96
  • secondary neoplasm of spleen (C78.89)Inherited from C81-C96

Related Codes

Official
C84.70Anaplastic large cell lymphoma, ALK-negative, unspecified siteC84.71Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face, and neckC84.72Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodesC84.73Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodesC84.74Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb

Includes

Official

No Includes notes are included in this display for C84.7B. Check the code and parent instructions in the Code Book.

Excludes 1

Official
  • personal history of non-Hodgkin lymphoma (Z85.72)Inherited from C84, C84.7
  • primary cutaneous CD30-positive T-cell proliferations (C86.6-)Inherited from C84, C84.7

Code First

Official

No Code First sequencing instructions are included in this display for C84.7B. Check the code and parent instructions in the Code Book.

Use Additional

Official

No Use Additional Code instructions are included in this display for C84.7B. Check the code and parent instructions in the Code Book.

Code Also

Official

No Code Also instructions are included in this display for C84.7B. Check the code and parent instructions in the Code Book.

Buddy Documentation Tip

HCC Buddy guidance
Original pathology confirming ALCL ALK-negative
Oncologist documentation explicitly stating remission status
Most recent imaging confirming no active disease
Surveillance plan documented

MEAT Support

HCC Buddy guidance
Original pathology confirming ALCL ALK-negative
Oncologist documentation explicitly stating remission status
Most recent imaging confirming no active disease
Surveillance plan documented

Audit Caution

HCC Buddy guidance
Using active disease code when remission is documented
Coding remission before oncologist formally documents it
Prematurely converting to personal history code while patient is under active surveillance
Confusing ALK-positive remission code with ALK-negative remission code

Common Mistakes

HCC Buddy guidance
C84.6A — ALCL ALK-positive, in remission: Different ALK status; verify original pathology
C84.70 — ALCL ALK-negative, unspecified (active): Active disease, not remission
Z85.79 — Personal history of malignant neoplasm of lymphoid tissue: History code implies resolved disease; premature during active remission monitoring
C84.4A — PTCL-NOS, in remission: Different lymphoma subtype

Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →

Is C84.7B an HCC code?

Yes. C84.7B (Anaplastic large cell lymphoma, ALK-negative, in remission) maps to HCC 19, Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers under the CMS-HCC V28 risk adjustment model, with a source-labeled community non-dual aged reference coefficient of 1.798. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes. It is billable for payment year 2026.

Coder answer: C84.7B is billable and maps to V28 HCC 19, Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.

Code
C84.7B
Description
Anaplastic large cell lymphoma, ALK-negative, in remission
HCC (V28)
HCC 19 — Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers
RAF reference coefficient
1.798
Billable
Yes
Payment year
2026

HCC Category Mapping

V28HCC 19, Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers
1.798
ESRDHCC 10, Lymphoma and Other Cancers
Not separately weighted
RxHCCHCC 21, Lymphomas and Other Hematologic Cancers
Not separately weighted

These are source-labeled model coefficients, not member totals. A category may still be removed by hierarchy or model cleanup rules. Weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member context, hierarchy and cleanup rules, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains available for historical review.

Work C84.7B in the Code Book — tabular path, V28 RAF reference, and MEAT checklist →

MEAT review for C84.7B

For C84.7B, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule.

  • MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
  • EEvaluate: test results, medication response, or physical findings reviewed by the provider
  • AAssess: explicit mention in the assessment or plan with acknowledgment of status
  • TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Coder workflow notes

Get the V28 mapping + MEAT cheat sheet

One printable reference: check representative V28 mappings and the documentation reminders your note needs. Free, no card.

Free PDF. No card. Unsubscribe anytime.

What This Code Means

C84.7B is the ICD-10-CM diagnosis code for anaplastic large cell lymphoma, alk-negative, in remission. This is a type of aggressive blood cancer (lymphoma) that affects immune cells and does not have a specific genetic marker (ALK-negative), and the patient is currently in remission, meaning the cancer is not actively growing or detectable. C84.7B sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).

Under the CMS-HCC V28 risk adjustment model, C84.7B maps to Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers (HCC 19) with a source-labeled community, non-dual, aged reference coefficient of 1.798. No V24 mapping is shown for C84.7B; use the applicable model and payment year when reviewing the V28 mapping. For CY2026 non-PACE Medicare Advantage, CMS uses 100% of the 2024 CMS-HCC model (V28). PACE uses a separate model blend. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes.

Ensure documentation clearly states 'in remission' status, as this affects staging and prognosis coding; remission status must be explicitly documented by the physician. For C84.7B, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, source-labeled coefficient references, and MEAT documentation criteria for C84.7B sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

  • •Ensure documentation clearly states 'in remission' status, as this affects staging and prognosis coding; remission status must be explicitly documented by the physician
  • •Verify the ALK-negative status is confirmed through pathology or molecular testing results, as this distinguishes it from ALK-positive anaplastic large cell lymphoma (C84.7A)

Clinical Significance

Anaplastic large cell lymphoma, ALK-negative, in remission indicates the patient has achieved disease control from this aggressive lymphoma. ALK-negative ALCL has lower remission rates than ALK-positive disease, making this a notable clinical milestone. Ongoing surveillance is essential due to the higher relapse risk associated with ALK-negative status.

Documentation Requirements

  • ✓Original pathology confirming ALCL ALK-negative
  • ✓Oncologist documentation explicitly stating remission status
  • ✓Most recent imaging confirming no active disease
  • ✓Surveillance plan documented
  • ✓Treatment history including regimen received

Commonly Confused Codes

  • •C84.6A: ALCL ALK-positive, in remission: Different ALK status; verify original pathology
  • •C84.70: ALCL ALK-negative, unspecified (active): Active disease, not remission
  • •Z85.79: Personal history of malignant neoplasm of lymphoid tissue: History code implies resolved disease; premature during active remission monitoring
  • •C84.4A: PTCL-NOS, in remission: Different lymphoma subtype

Child Codes

C84.70Anaplastic large cell lymphoma, ALK-negative, unspecified site
HCC 19
C84.71Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face, and neck
HCC 19
C84.72Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes
HCC 19
C84.73Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes
HCC 19
C84.74Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb
HCC 19
C84.75Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb
HCC 19
C84.76Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes
HCC 19
C84.77Anaplastic large cell lymphoma, ALK-negative, spleen
HCC 19
C84.78Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites
HCC 19
C84.79Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites
HCC 19
C84.7AAnaplastic large cell lymphoma, ALK-negative, breast
HCC 19
C84.7BAnaplastic large cell lymphoma, ALK-negative, in remission
HCC 19

Code Hierarchy

└C84Mature T/NK-cell lymphomas└C84.7Anaplastic large cell lymphoma, ALK-negative└C84.7BAnaplastic large cell lymphoma, ALK-negative, in remission
└C84.7BAnaplastic large cell lymphoma, ALK-negative, in remission

C84.7B code history

Code setChange
FY2025 (effective Oct 1, 2024)Added to the code set

Source: official CMS ICD-10-CM order and addenda files, FY2016 through FY2027.

Also searched as

  • C84 7B
  • C847B

For C84.7B, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule.

C84.7B maps to CMS-HCC V28 category 19, Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers. See the ICD-10 to HCC mapping hub for how the V28 crosswalk works. The mapping identifies a payment HCC category for C84.7B. Review its source-labeled HCC coefficient above, check the RAF Calculator with complete member context for CMS-HCC V28 PY2026, and confirm the documentation the chart needs before the code is submitted. HCC Buddy shows no RAF score unless every required source and calculation check passes.

More on C84.7B

Referenced in blog posts

Work C84.7B in HCC Buddy

Open C84.7B in the Code Book for the full Index-to-Tabular path, MEAT checklist, and V28 HCC mapping, or in the Encoder to code from a keyword search. Pro includes 7 days to try everything, no card required.

Open in Code BookOpen in EncoderStart Pro